-
Breast Invasive Carcinoma (TCGA, Firehose Legacy)
- Description
TCGA Breast Invasive Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 1,108 carcinomas from 1,101 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...
- Subject
-
Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularDNA Mutational AnalysisSkin Neoplasms
- Access Rights
- Free to All
-
The Angiosarcoma Project (Provisional): an ongoing patient-driven initiative.
- Description
Dataset Summary Description: "This provisional dataset is currently derived from 83 samples, including tumor specimens (FFPE and cfDNA) from 62 angiosarcoma patients subjected to WES (along with matched germline WES). This study includes genomic data, patient-reported data (pre-pended as PRD), medical record data (MedR), and pathology report data (PATH). As these data were generated in a research...
- Subject
-
Basal Cell CarcinomaBreast NeoplasmsColorectal NeoplasmsHemangiosarcomaHodgkin DiseaseLeukemia, Lymphocytic, Chronic, B-CellProstatic NeoplasmsRectal NeoplasmsSkin NeoplasmsThyroid NeoplasmsUterine NeoplasmsVulvar Neoplasms
- Access Rights
- Free to All
-
Phenotyping tumor-immune microenvironment in vivo in skin cancer patients
- Authors
- Sahu, AditiByers, CandiceChandrani, PratikTembo, Teguru C.1 more author(s)...
- Description
Summary from GEO: "Phenotyping of tumors into hot, altered, or cold based on assessment of only T-cell infiltration in static tumor biopsies provides suboptimal prediction of immunotherapy response. In vivo dynamic mechanisms within the tumor microenvironment such as tumor angiogenesis and leukocyte trafficking also play a central role in modulating anti-tumor immunity and therefore immunotherapy...
- Subject
-
Basal Cell CarcinomaGene ExpressionImmunotherapyPhenotypeSkin Neoplasms
- Access Rights
- Free to All